Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection

Completed

• Conditions: Vitreomacular Interface; Anti-VEGF Treatment; Diabetic Macular Edema
• Interventions: Drug: Intravitreal Ranibizumab injection

• Registration Number: NCT02933905
• Lead Sponsor: Fundació Institut Germans Trias i Pujol

Brief Summary

Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01
• Primary Completion: 2015-01
• Study Completion: 2016-06
• Status Verified: 2016-10
• Study First Submitted: 2016-10-12
• Study First Submitted QC: 2016-10-12
• Study First Posted: 2016-10-14
• Last Update Submitted: 2016-10-14
• Last Update Posted: 2016-10-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• diabetic macular edema treatable with antiangiogenic drugs

Exclusion Criteria

• age under 18
• cardiovascular events during the last year
• previous vitrectomy
• previous macular edema treatment during the last 4 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Non-PVD subjects	Intravitreal Ranibizumab injection	Patients with no PVD on SD-OCT at basal visit
PVD subjects	Intravitreal Ranibizumab injection	Patients with PVD on SD-OCT at basal visit

Primary Outcome Measures

Name	Time	Method
Change in best-corrected visual acuity	One year

Secondary Outcome Measures

Name	Time	Method
Number of ranibizumab injections	One year
Change in central macular thickness	One year